AMRX

Amneal Pharmaceuticals is a diversified generic and specialty drugmaker that has executed a genuine operational turnaround. Revenue grew 8.0% to $3.02B (extending steady gains from $2.09B in FY2021), operating income jumped 58.1% to $394M at a 13.1% operating margin, and the company swung to GAAP profitability with net income of $72.1M after losses in FY2022-FY2024. Gross margin of 36.9% is solid for generics, R&D investment continues at $186M, and operating cash flow rose 15.2% to $340M — the business is now both growing and cash-generative.

The overhang is the balance sheet. Amneal carries $2.57B of long-term debt (up 18.7%) and stockholders' equity is slightly negative at -$70.8M (with a -$535M accumulated deficit), the legacy of prior losses and a leveraged capital structure. The -101.8% ROE is an arithmetic artifact of negative equity and should be ignored, but the leverage is real: the heavy interest burden is precisely why a $394M operating income converts to only $72.1M of net income (a thin 2.4% net margin). The encouraging signs are that cash more than doubled to $282M, the current portion of debt fell 97%, and current liabilities dropped 22% — near-term liquidity is improving.